C3orf22 Inhibitors
The array of inhibitors targeting C3orf22 delineates a comprehensive approach to tempering the protein's activity through interference with pivotal signaling pathways. Compounds such as Rapamycin and LY 294002 exert their inhibitory effects by disrupting the mTOR and PI3K/AKT pathways, respectively, which are essential for processes that C3orf22 may be reliant on, such as protein synthesis and cellular proliferation. Moreover, MEK inhibitors like U0126 and PD 98059 are presumed to diminish C3orf22 activity by obstructing the MAPK/ERK pathway, potentially affecting C3orf22's regulatory functions if it is indeed modulated by this route. Additionally, SB 203580 and SP600125 target the p38 MAPK and JNK signaling pathways, providing further avenues for reducing C3orf22 activity by altering transcription and gene expression mechanisms relevant to its operation.
In the pursuit of comprehensively inhibiting C3orf22, additional molecules such as Gefitinib and Erlotinib, which are EGFR tyrosine kinase inhibitors, may indirectly lead to a decrease in C3orf22 activity by impeding downstream effectors that C3orf22 could utilize. Bortezomib's proteasome inhibition might also indirectly diminish C3orf22 activity by altering the degradation rate of proteins that control its activity. Furthermore, inhibitors like Sorafenib and Sunitinib, which target RAF kinase and various receptor tyrosine kinases, respectively, could subdue C3orf22 activity by intervening in signaling pathways responsible for cell growth and proliferation, thereby indirectly impacting the functional dynamics of C3orf22. Together, these compounds represent a targeted strategy to inhibit C3orf22 by addressing specific biochemical pathways and cellular processes that are essential for its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that suppresses the mTOR pathway, which is essential for protein synthesis and cell growth, leading to decreased activity of C3orf22 as it may rely on these cellular processes for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/AKT signaling pathway, resulting in reduced phosphorylation and activation of downstream targets, potentially diminishing the activity of C3orf22 if it is functionally connected to this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that inhibits p38-mediated signaling, which could lead to reduced activity of downstream proteins including C3orf22 if it is implicated in stress response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that blocks the MAPK/ERK pathway, potentially leading to diminished C3orf22 activity if it is regulated by or dependent on this pathway for its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK1/2 specific inhibitor that interferes with the MAPK/ERK signaling, potentially diminishing the activity of C3orf22 if it plays a role in this signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK signaling which could decrease C3orf22 activity by altering transcription factor activity and gene expression related to this pathway. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR tyrosine kinase inhibitor that could potentially diminish C3orf22 activity by blocking downstream signaling pathways that might be crucial for the function of C3orf22. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Another EGFR inhibitor that, like Gefitinib, could indirectly lead to decreased activity of C3orf22 by inhibiting essential signaling pathways for its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that may indirectly decrease the functional activity of C3orf22 by preventing the degradation of regulatory proteins that inhibit C3orf22 activity or by promoting the accumulation of proteins that suppress its function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A RAF kinase inhibitor that may lead to decreased C3orf22 activity by inhibiting the RAF/MEK/ERK pathway, potentially impacting the function of C3orf22 if it is associated with this pathway. | ||||||